Astrazeneca PLC (AZN) Receives Hold Rating from Leerink Swann
Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating restated by investment analysts at Leerink Swann in a research note issued to investors on Sunday. They currently have a $35.00 price objective on the stock. Leerink Swann’s target price indicates a potential upside of 8.39% from the company’s previous close.
Several other research firms also recently weighed in on AZN. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Shore Capital reissued a “hold” rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. Argus initiated coverage on Astrazeneca PLC in a research report on Tuesday, July 12th. They set a “hold” rating on the stock. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. Finally, TheStreet raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Friday, July 22nd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $37.56.
Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Friday. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04. The stock has a market cap of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75. The firm’s 50-day moving average price is $33.23 and its 200 day moving average price is $30.79.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/astrazeneca-plc-azn-receives-hold-rating-from-leerink-swann.html
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.07. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.21 EPS. On average, analysts anticipate that Astrazeneca PLC will post $2.97 earnings per share for the current year.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were paid a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 78.29%.
A number of large investors have recently added to or reduced their stakes in the stock. Veritable L.P. boosted its stake in Astrazeneca PLC by 0.5% in the second quarter. Veritable L.P. now owns 9,972 shares of the company’s stock worth $301,000 after buying an additional 54 shares during the period. Fifth Third Bancorp boosted its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the period. Logan Capital Management Inc. raised its position in shares of Astrazeneca PLC by 0.6% in the first quarter. Logan Capital Management Inc. now owns 19,698 shares of the company’s stock worth $554,000 after buying an additional 109 shares in the last quarter. Independent Portfolio Consultants Inc. raised its position in shares of Astrazeneca PLC by 0.6% in the third quarter. Independent Portfolio Consultants Inc. now owns 22,720 shares of the company’s stock worth $738,000 after buying an additional 145 shares in the last quarter. Finally, National Planning Corp raised its position in shares of Astrazeneca PLC by 1.0% in the second quarter. National Planning Corp now owns 17,742 shares of the company’s stock worth $607,000 after buying an additional 175 shares in the last quarter. Institutional investors own 11.39% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.